EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer By Ogkologos - November 5, 2024 659 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with early breast cancer at high risk of recurrence Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR When Ellen Found Out There Was A Grieving Mother In The... March 12, 2019 7 Steps for Developing Microhabits During Cancer That Can Improve Your... November 2, 2023 Abnormal Results from Prenatal Blood Test Could Point to Cancer in... February 21, 2025 Abiraterone Acetate Plus Prednisone and LHRH Analogue is Active and Safe... October 4, 2021 Load more HOT NEWS India’s First Homegrown CAR T-Cell Therapy Has Roots in NCI Collaboration Sheriff’s Sergeant Is Now Fighting Stage III Breast Cancer After Missing... Inpatient Mammography May Help Solve Issue of Low Screening Rates, Especially... Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients...
